Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer.
Saved in:
| Title: | Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. |
|---|---|
| Authors: | Elakad O; Institute of Pathology, University Medical Center, Goettingen, Germany., Häupl B; Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany., Labitzky V; Institute for Anatomy and Experimental Morphology, University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Yao S; Institute of Pathology, University Medical Center, Goettingen, Germany., Küffer S; Institute of Pathology, University Medical Center, Goettingen, Germany., von Hammerstein-Equord A; Department of Thoracic and Cardiovascular Surgery, University Medical Center, Goettingen, Germany., Danner BC; Department of Thoracic and Cardiovascular Surgery, University Medical Center, Goettingen, Germany., Jücker M; Center for Experimental Medicine, Institute of Biochemistry and Signal Transduction, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Urlaub H; Bioanalytical Mass Spectrometry Group, Max Planck Institute for Biophysical Chemistry, Goettingen, Germany., Lange T; Institute for Anatomy and Experimental Morphology, University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Ströbel P; Institute of Pathology, University Medical Center, Goettingen, Germany., Oellerich T; Department of Medicine II, Hematology/Oncology, Goethe University, Frankfurt, Germany.; German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany.; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany., Bohnenberger H; Institute of Pathology, University Medical Center, Goettingen, Germany. Hanibal.bohnenberger@med.uni-goettingen.de. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2022 Jul 19; Vol. 6 (1), pp. 52. Date of Electronic Publication: 2022 Jul 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2397-768X |
|---|---|
| DOI: | 10.1038/s41698-022-00296-2 |
